HealthDay News — Socioeconomic factors are linked to an increased risk for age-related macular degeneration (AMD), according to a study published online July 1 in Health Data Science.
SOL-1 expected to be fully randomized by YE 2024 with topline data expected in Q4 2025 Cash balance of $427.2M as of September 30, 2024, expected to fund operations into 2028 Ocular to host a Q3 2024 ...
EyePoint Pharmaceuticals' lead product, EYP-1901, shows promising phase 2 results for wet AMD and DME. Read more about EYPT ...
These are the best vitamins and supplements for eye health, which are great for supporting your vision and helping you take ...
Age-related macular degeneration (ARMD) is the leading cause of severe vision loss in the developed world for people over 55 ...
If you want to see better in the dark, a handful of pistachios a day have been found to keep your eyes healthy and protect ...
You may have seen advertisements claiming to eliminate the need for eyeglasses through vision therapy or vision training – ...
The US Food and Drug Administration has FDA has granted marketing authorization to a form of light therapy as the first-ever ...
Opthea is a clinical-stage biotech firm developing Sozinibercept, targeting VEGF-C and VEGF-D for wet AMD, with Phase 3 ...
The FDA has cleared its first light-based therapy for dry age-related macular degeneration—which the agency described as ...
Medpage Today on MSN8d
FDA Grants Market Authorization to Light-Therapy System for Dry AMDThe FDA announced marketing authorization of a form of light therapy as the first-ever treatment for dry age-related macular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback